Rethink Imaging
Radiopharmaceutical Therapy: How Molecular Imaging Is Targeting Cancer Treatment | Dr. Phil Mulugeta
November 19, 2026
In this episode of Rethink Imaging, host Chris St. John sits down with nuclear medicine specialist Dr. Phil Mulugeta to discuss the rapid ascent of radiopharmaceutical therapy and theranostics. Dr. Mulugeta unpacks the molecular "lock-and-key" mechanics behind targeted radioligands, the clinical impact of PSMA PET and Lutetium-177 in prostate cancer, hardware innovations like total body PET scanners, and why streamlining care delivery is critical for the future of molecular medicine.
Nuclear medicine is undergoing a historic shift, moving beyond purely diagnostic physiologic imaging into targeted, biologically driven oncologic therapy. In this episode of Rethink Imaging, host Chris St. John is joined by Dr. Phil Mulugeta to explore the science, clinical breakthroughs, and practical realities of radiopharmaceutical therapy (theranostics).

Dr. Mulugeta details how radiopharmaceuticals function using a "lock, key, and keychain" model to deliver ionizing payloads directly to malignant cells while minimizing damage to healthy tissue. The conversation dives into the clinical transformation sparked by PSMA PET imaging and Lutetium-177 treatments from identifying previously invisible occult metastases to extending survival and preserving quality of life in advanced, chemotherapy exhausted prostate cancer patients. 

He also covers major hardware leaps, including total-body PET scanners that cut scan times to five minutes at drastically lower radiation doses. Finally, they discuss competitive dynamics against antibody-drug conjugates, how to prevent delays in clinical workflows, and emerging uses in Alzheimer's disease and neurodegenerative imaging.


What You'll Learn: 

Youtube Chapters: 


Rethink Imaging Podcast is handcrafted by our friends over at: fame.so